ODT Staff03.01.22
Bioventus Inc. is welcoming a new C-Suite member into the fold.
The company has named Mark Singleton as senior vice president, chief financial officer (CFO), and principal accounting officer. Singleton will begin working for Bioventus on March 21. “I’m excited to join the Bioventus team, and I strongly believe that we can leverage the company’s portfolio to capitalize on the opportunities we have in front of us. I am looking forward to working closely with Ken, the board, and the rest of the executive team to continue growing the company, enhancing operating margins, and extending its market leadership,” said Singleton.
Singleton brings to Bioventus more than two decades of experience in operational finance and M&A at large and multinational organizations. Most recently, he served as vice president of Finance, Americas, for Teleflex Incorporated, where he was responsible for the $1.7 billion Americas business. Before that, Singleton was vice president of Finance of Teleflex’s Vascular business (he joined the company in 2014). He was also involved in initiating the Vascular Solutions acquisition, which became a separate business unit at Teleflex. Before his Teleflex tenure, Singleton spent nearly two decades at Lenovo/IBM, where he worked in various senior leadership positions, including EMEA CFO, Western Europe CFO, North America CFO, and Think Business Group CFO.
Singleton earned his MBA from Duke University’s Fuqua School of Business and completed his bachelor of science degree in finance from Purdue University.
“We are thrilled to welcome Mark to our executive team. He has demonstrated a strong track record of achievement during his time at both Teleflex and Lenovo/IBM,” Bioventus CEO Ken Reali said. “We believe Mark’s broad operational experience and his ability to drive efficiencies across multinational organizations will serve us well as we enhance our scale and extend Bioventus’ leadership in the markets we serve today. Mark is also a terrific cultural fit with our high performance organization.”
Bioventus delivers clinically proven, cost-effective products with offerings for pain treatment, restorative therapies, and surgical solutions.
The company has named Mark Singleton as senior vice president, chief financial officer (CFO), and principal accounting officer. Singleton will begin working for Bioventus on March 21. “I’m excited to join the Bioventus team, and I strongly believe that we can leverage the company’s portfolio to capitalize on the opportunities we have in front of us. I am looking forward to working closely with Ken, the board, and the rest of the executive team to continue growing the company, enhancing operating margins, and extending its market leadership,” said Singleton.
Singleton brings to Bioventus more than two decades of experience in operational finance and M&A at large and multinational organizations. Most recently, he served as vice president of Finance, Americas, for Teleflex Incorporated, where he was responsible for the $1.7 billion Americas business. Before that, Singleton was vice president of Finance of Teleflex’s Vascular business (he joined the company in 2014). He was also involved in initiating the Vascular Solutions acquisition, which became a separate business unit at Teleflex. Before his Teleflex tenure, Singleton spent nearly two decades at Lenovo/IBM, where he worked in various senior leadership positions, including EMEA CFO, Western Europe CFO, North America CFO, and Think Business Group CFO.
Singleton earned his MBA from Duke University’s Fuqua School of Business and completed his bachelor of science degree in finance from Purdue University.
“We are thrilled to welcome Mark to our executive team. He has demonstrated a strong track record of achievement during his time at both Teleflex and Lenovo/IBM,” Bioventus CEO Ken Reali said. “We believe Mark’s broad operational experience and his ability to drive efficiencies across multinational organizations will serve us well as we enhance our scale and extend Bioventus’ leadership in the markets we serve today. Mark is also a terrific cultural fit with our high performance organization.”
Bioventus delivers clinically proven, cost-effective products with offerings for pain treatment, restorative therapies, and surgical solutions.